keyword
MENU ▼
Read by QxMD icon Read
search

Fatigue and MS

keyword
https://www.readbyqxmd.com/read/28643601/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-sweden
#1
Lou Brundin, Gisela Kobelt, Jenny Berg, Daniela Capsa, Jennifer Eriksson
BACKGROUND: To assess the value of management strategies in multiple sclerosis (MS), outcome data have to be combined with cost data. This requires that cost data be regularly updated. OBJECTIVE AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity and health-related quality of life (HRQoL). Descriptive analyses are presented by level of severity; costs are estimated in the societal perspective, in 2015 SEK...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643600/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-italy
#2
Mario Battaglia, Gisela Kobelt, Michela Ponzio, Jenny Berg, Daniela Capsa, Johan Dalén
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643599/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-austria
#3
Thomas Berger, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643598/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-belgium
#4
Benedicte Dubois, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643597/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-spain
#5
Celia Oreja-Guevara, Gisela Kobelt, Jenny Berg, Daniela Capsa, Jennifer Eriksson
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) where lifetime costs and outcomes cannot be observed, outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643596/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-switzerland
#6
Pasquale Calabrese, Gisela Kobelt, Jenny Berg, Daniela Capsa, Jennifer Eriksson
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643595/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-the-netherlands
#7
Bernard Uitdehaag, Gisela Kobelt, Jenny Berg, Daniela Capsa, Johan Dalén
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643593/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-germany
#8
Peter Flachenecker, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643591/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-hungary
#9
Márta Péntek, Gisela Kobelt, Jenny Berg, Daniela Capsa, Johan Dalén, Zita Bíró, Klotild Mátyás, Sámuel Komoly
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643590/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-russia
#10
Alexey Boyko, Gisela Kobelt, Jenny Berg, Olga Boyko, Ekaterina Popova, Daniela Capsa, Jennifer Eriksson
BACKGROUND: In order to assess the value of management strategies in multiple sclerosis (MS), outcome data have to be combined with cost data. This, in turn, requires that cost data be regularly updated. OBJECTIVE AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity and health-related quality of life (HQoL). Descriptive analyses are presented by level of severity; costs are estimated in the societal perspective, in RUB 2015...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643589/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-denmark
#11
Peter Vestergaard Rasmussen, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl
BACKGROUND: To estimate the value of treatments in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with cost data. This, in turn, requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643588/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-france
#12
Christine Lebrun-Frenay, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643587/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-the-united-kingdom
#13
Alan Thompson, Gisela Kobelt, Jenny Berg, Daniela Capsa, Jennifer Eriksson, David Miller
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643586/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-poland
#14
Krzysztof Selmaj, Gisela Kobelt, Jenny Berg, Ewa Orlewska, Daniela Capsa, Johan Dalén
BACKGROUND: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVE AND METHODS: This study is part of a cross-sectional retrospective study in 16 European countries collecting current data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643585/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-portugal
#15
Maria José Sá, Gisela Kobelt, Jenny Berg, Daniela Capsa, Johan Dalén
BACKGROUND: In order to assess the value of management strategies in multiple sclerosis (MS), outcome data have to be combined with cost data. This, in turn, requires that cost data be regularly updated. OBJECTIVE AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity and health-related quality of life (HRQoL). Descriptive analyses are presented by level of severity; costs are estimated in the societal perspective, in EUR 2015...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643584/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-of-the-czech-republic
#16
Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28641771/fatigue-in-multiple-sclerosis-is-it-related-to-cytokines-and-hypothalamic-pituitary-adrenal-axis
#17
Aylin Akcali, Fatma Zengin, Sefika Nur Aksoy, Orhan Zengin
BACKGROUND: Fatigue is a common symptom of Multiple Sclerosis (MS) that diminishes the quality of life of patients, but its exact mechanism remains poorly understood. There is not a generally adopted scale to determine MS fatigue. Studies that investigated physiopathology of fatigue symptom have shown dysregulation of hypothalamic-pituitaryadrenal (HPA) axis. In the current study, we aimed to compare the results obtained with two separate scales, namely the Fatigue Severity Scale (FSS) and the Neurological Fatigue Index-Multiple Sclerosis (NFI-MS), and assess the relationship between fatigue and serum IL-1β, TNF-α, IL-35, IL-2, IL-10, ACTH, cortisol, α-MSH, β-MSH, γ-MSH and CLIP (Corticotropinlike intermediate lobe peptide) in MS patients categorized as fatigued and non-fatigued on the basis of FSS scores...
July 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28641055/long-term-safety-evaluation-of-natalizumab-for-the-treatment-of-multiple-sclerosis
#18
Marinella Clerico, Carlo Alberto Artusi, Alessandra Di Liberto, Simona Rolla, Valentina Bardina, Pierangelo Barbero, Stefania Federica De Mercanti, Luca Durelli
Introduction Natalizumab is a humanized monoclonal antibody highly effective in relapsing-remitting multiple sclerosis (MS). Important concerns about its safety have been pointed out because of the risk of progressive multifocal leukoencephalopathy (PML), caused by the opportunistic John-Cunningham virus (JCV). Areas covered This review analyzes all the safety aspects related to the use of natalizumab in MS patients. Fatigue and allergic reactions are not-severe adverse events (AEs) occurring more frequently than placebo and no differences in serious AEs (SAE) have been observed comparing to interferon-β1a during clinical trials...
June 22, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28638709/-cure-for-multiple-sclerosis-ms-evolving-views-of-therapy-goals-in-patients-on-different-stages-of-the-disease-a-pilot-study-in-a-cohort-of-polish-ms-patients
#19
Weronika Chacińska, Marta Brzostowska, Monika Nojszewska, Aleksandra Podlecka-Piętowska, Wiesław W Jędrzejczak, Emilian Snarski
INTRODUCTION: New aggressive treatments promise improvement of results in the treatment of multiple sclerosis (MS), however, with high risk of serious complications. In this study, we analyzed patients' acceptance for risks connected with the MS treatment. METHODS: The study was designed as a prospective nonanonymous online questionnaire. Responders were asked about the definition of the "cure" for MS and crucial goals in the treatment. RESULTS: One hundred and eighty patients filled in the questionnaire (129 women and 51 men), and the mean age was 33 years (SD = 10...
June 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28638707/sexual-dysfunction-in-female-patients-with-relapsing-remitting-multiple-sclerosis
#20
Pawel Bartnik, Aleksandra Wielgoś, Joanna Kacperczyk, Katarzyna Pisarz, Iwona Szymusik, Aleksandra Podlecka-Piętowska, Beata Zakrzewska-Pniewska, Miroslaw Wielgoś
INTRODUCTION: Sexual dysfunction (SD) is one of the common symptoms of multiple sclerosis (MS) and is often underdiagnosed, especially in women. Relapsing-remitting multiple sclerosis (RRMS) is the most widespread form of the disease, but the data on SD occurrence in this particular group of patients is limited. The aim of the study was to analyze the associations between demographic factors, symptoms and signs of MS, psychiatric comorbidities and SD in female patients with RRMS. MATERIAL & METHODS: A subgroup of 86 sexually active women with RRMS out of 218 total MS respondents was analyzed...
June 2017: Brain and Behavior
keyword
keyword
47750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"